Antimicrobial susceptibility of acinetobacter clinical isolates and emerging antibiogram trends for nosocomial infection management

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 49, Issue 3, 2016, Pages 300-304

  Sohail, Muhammad ^a,b   Rashid, Abid ^c   Aslam, Bilal ^c   Waseem, Muhammad ^c   Shahid, Muhammad ^c   Akram, Muhammad ^d   Khurshid, Mohsin ^c   Rasool, Muhammad Hidayat ^c  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

^b Chughtais Lahore Lab   (Pakistan)

^c GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

^d COMSATS Institute of Information Technology ^*  (Pakistan)

Author keywords

Acinetobacter; Antibiotic resistance; Carbapenems; Nosocomial infections; Prevalence

Indexed keywords

AMIKACIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; HOSPITAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; AGE DISTRIBUTION; CLASSIFICATION; COMPARATIVE STUDY; CROSS INFECTION; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ACINETOBACTER; ACINETOBACTER INFECTIONS; AGE DISTRIBUTION; ANTI-BACTERIAL AGENTS; CROSS INFECTION; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84976636243     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/0037-8682-0111-2016     Document Type: Article

References (26)

1. Allen S, Procop G, Schreckenberger P. Guidelines for the collection, transport, processing, analysis, and reporting of cultures from specific specimen sources. In: Winn WC, Koneman EE, editors. Koneman’s Color Atlas and Textbook of Diagnostic Microbiology. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 68-105.
2. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9:148-165.
3. Husni RN, Goldstein LS, Arroliga AC, Hall GS, Fatica C, Stoller JK, et al. Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest 1999; 115:1378-1382.
4. Van Looveren M, Goossens H, Group AS. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10:684-704.
5. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 20th informational supplement. Wayne, PA: CLSI; 2010, CLSI document M100-S120. 2010.
6. Lyytikainen O, Koljalg S, Harma M, Vuopio-Varkila J. Outbreak caused by two multi-resistant Acinetobacter baumannii clones in a burns unit: emergence of resistance to imipenem. J Hosp Infect 1995; 31:41-54.
7. Seifert H, Baginski R, Schulze A, Pulverer G. Antimicrobial susceptibility of Acinetobacter species. Antimicrob Agents Chemother 1993; 37:750-753.
8. Vila J, Marcos A, Marco F, Abdalla S, Vergara Y, Reig R, et al. In vitro antimicrobial production of beta-lactamases, aminoglycosidemodifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1993; 37:138-141.
9. Cowan. Cowan and Steel’s Manual for the Identification of Medical Bacteria. 2nd edition. Cambridge: Cambridge University Press; 1974.
10. Chang KC, Lin MF, Lin NT, Wu WJ, Kuo HY, Lin TY, et al. Clonal spread of multidrug-resistant Acinetobacter baumannii in eastern Taiwan. J Microbiol Immunol Infect 2012; 45:37-42.
11. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39:183-190.
12. Suri A, Mahapatra AK, Kapil A. Acinetobacter infection in neurosurgical intensive care patients. Natl Med J India 2000; 13:296-300.
13. Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 1999; 281:67-71.
14. Turner PJ, Greenhalgh JM, Group MS. The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000. Clin Microbiol Infect 2003; 9:563-567.
15. Turner PJ. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis 2008; 60:185-192.
16. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51:3471-3484.
17. Cisneros JM, Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect 2002; 8:687-693.
18. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006; 12:315-321.
19. Rodloff AC, Leclercq R, Debbia EA, Canton R, Oppenheim BA, Dowzicky MJ. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial. Clin Microbiol Infect 2008; 14:307-314.
20. Souli M, Kontopidou FV, Koratzanis E, Antoniadou A, Giannitsioti E, Evangelopoulou P, et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006; 50:3166-3169.
21. Seifert H, Stefanik D, Wisplinghoff H. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 2006; 58:1099-1100.
22. Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents 2008; 32:29-32.
23. Dent LL, Marshall DR, Pratap S, Hulette RB. Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infect Dis 2010; 10:196.
24. Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. Ann Clin Microbiol Antimicrob 2007; 6:4.
25. McGregor JC, Elman MR, Bearden DT, Smith DH. Sex-and agespecific trends in antibiotic resistance patterns of Escherichia coli urinary isolates from outpatients. BMC Fam Pract 2013; 14:25.
26. Lu N, Hu Y, Zhu L, Yang X, Yin Y, Lei F, et al. DNA microarray analysis reveals that antibiotic resistance-gene diversity in human gut microbiota is age related. Sci Rep 2014; 4:4302.